Pfizer is involved in joint venture with GlaxoSmithKline to create new world-leading HIV company focused on research, development and commercialization of HIV medicines
Clients Pfizer, Inc.
Jones Day represented Pfizer, Inc. in its agreement with GlaxoSmithKline plc to create a new world-leading HIV company focused solely on research, development and commercialization of HIV medicines. GlaxoSmith Kline will initially hold an 85% equity interest in the new company and Pfizer will hold 15%. The transaction is expected to close in the fourth quarter of 2009.